Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum

Due Diligence Monitoring and Auditing of Third Party Vendors

October 28, 2008

Diana BorgesCompliance Manager
Teva Pharmaceuticals

Brian Dahl, Esq.
Director of Compliance
Teva Pharmaceuticals

Michele Girdharry
Manager
Huron Consulting Group

Paul Silver
Managing Director
Huron Consulting Group

Working with Third Parties, Vendors, and Strategic Partners

Agenda

- I. The Importance of Auditing & Monitoring Third-Party Vendors
- II. Balancing Business and Compliance Challenges When Auditing
- III. Criteria When Choosing a Third-Party Vendor to Audit
- IV. Planning The Audit
- V. Navigating Challenges that Arise from Audit Results
- VI. Capturing Compliance Requirements During the Contracting Process

The Importance of Auditing & Monitoring Third-Party Vendors

Monitoring & Auditing are Essential Parts of an Effective Compliance Program

- Pharmaceutical manufacturers are responsible for auditing and monitoring as part of an effective compliance program
 - -One of seven elements
 - Corporate Integrity Agreements
 - NV and MA require certification that a manufacturer has conducted audits a part of its compliance program
- Demonstrates "proactive" vs. "reactive" action by a manufacturer
- PhRMA Code states that companies should periodically monitor speaker programs for compliance with FDA regulatory requirements

Monitoring & Auditing Responsibility Extends to Third-Party Vendors

- All guidance and regulations make clear that pharmaceutical manufacturers are responsible for all vendor activities that involve a healthcare professional
- Some Corporate Integrity Agreements are holding companies accountable for vendor activity



Evaluating Operational Effectiveness and Process Efficiency


- Identifying areas for improvement in the business processes
- Assist in addressing future issues up front in the contracting process
- Provides documentation that may be necessary when corrective action is required (e.g. termination or modification of a contract, etc)
- Conduct due diligence on vendors you are looking to contract or who you may have inherited through acquisition



Balancing Business and Compliance Challenges when Auditing

Business Unit Challenges

- Sense of urgency to get things done
- Allocating additional time and resources while managing dayto-day operational responsibilities
- Difficulties in taking steps to remedy findings
 - -Entrenched vendor
 - -Too far along in negotiations



Compliance Challenges

- Creating compliance awareness with business units
- Diverting resources when a business unit needs a vendor cleared
- Choosing appropriate resources for an audit
- Getting access to people / documents / systems
- Addressing resistance from stakeholders and business units
- Determining what courses of action to take with audit results



Criteria When Choosing a Third-Party Vendor to Audit

Areas of Risk Identified Internally at the Company

- Interviews with key personnel to identify risks
 - -One-on-one sessions
 - -Casual conversations
- Internal audits, QA review or Finance may discover potential vendor issues



Current Government Investigations and Advisory Opinions Issued by the OIG

- Payments to physicians
- Off label Promotion
- Transparency
- Consider what direction investigative and enforcement actions will take:
 - Advisory Opinions
 - -Guidance provided by the FDA, DOJ and OIG
 - -OIG Work plan



Planning the Audit


Scope

- Based on potential reasons for the audit, determine the appropriate scope:
 - -Brand / Product / Business Unit
 - Activity Type
 - -Time period



Identifying Audit Resources

- An internal audit group may have the infrastructure and relationships to efficiently manage an audit for the Company
- An external resource can provide an independent perspective and will have a good understanding of regulatory and compliance issues important to pharmaceutical companies.
- A Teaming Approach



Establishing a Workplan and Timeline

- Determine the specific areas of risk to evaluate
- Develop a methodology to test controls in place for each functional area or process managed by a third party vendor
- Develop a timeline for the audit that balances business expectations and compliance obligations (e.g. NV, MA, etc.)



Sample Audit Plan

Area of Risk

| | Speaker Program Vendor Focus Area: | | APPROVAL PROCESS AND DOCUMENTATION | | | | | | | |
|---|---|---|--|---|-------------------------------------|---|---|---|-----|---------------|
| | Business Objective: | | The vendor must provide verification that a speaker program has been approved and conducted in accordance with Company policy and using approved promotional materials. The Company is committed to sponsoring speaker programs in order to educate and inform other healthcare | | | | | | | |
| | Business Risk/Impact: | | | | | | | | | |
| | | | professionals about the benefits, risks and appropriate uses of company products. Because of the potential impact to healthcare professionals, the approval process and content of a program must be carefully | | | | | | | |
| | | | examined to avoid implicating any elements of the Federal Anti-Kickback Statute, Stark Laws and even the | | | | | | | |
| | | | FCPA. | | | | | | | |
| | Control Objectives | | Control activities | | Effectiveness of control activities | | | | | Comments |
| | | Т | | 1 | 2 | 3 | 4 | 5 | N/A | |
| 1 | Process for Approving A Speaker Program: Vendor has followed approval guidelines provided by the Company when planning a speaker program. | | Has the vendor submitted all required documentation: itemized expenses, invitee list, promotional material, venue information? Has the vendor reviewed the speaker's qualifications and training requirements in accordance with Company policy? Overall self-assessment: | | | | | | | - Audit Tests |

Controls that support risk area

Navigating Challenges That Arise from Audit Results

Determining Appropriate Courses of Action

- Prioritizing audit findings
- Determine what "buy-in" or approval will be needed
- Determine what internal resources and effort are available
- Responsibility for resolving issues should be assigned to the business unit
 - Compliance should provide guidance and oversight to the remediation plan
- Numerous findings may require a more comprehensive or follow-up audit
- Systemic findings may require modification or review of the vendor relationship

Determining who is Responsible for Resolving Risks

- Identify all key stakeholders in the business process (e.g. Business unit, Compliance, Legal, etc.)
- Determine who should own the responsibility in the Business unit for:
 - Managing the action plan
 - Reviewing and monitoring the action plan
 - -Evaluating the effectiveness of action plan



Potentially Terminating a Contract

- How much has been invested in the relationship?
- What will be the impact on the business unit?
- How long will it take to choose a new vendor?
- How much will it cost to replace a vendor (i.e. from identifying a new vendor, to going "live")?




Capturing Compliance Requirements During the Contracting Process: Lessons Learned

Considerations During the Contracting Process

- Teaming with Procurement to reinforce compliance
- Ensure vendor can comply with company policies, SOPs and Business rules
 - Consider requirements when co-promote partner is involved
- Establish a process for communicating process and management changes that must be approved by the Company
- Require company-specific training for vendor representatives and contractors
- Establish periodic auditing of program

Considerations During the Contracting Process

- Define termination provisions
- Establish scheduled reporting requirements for expenses and documentation (i.e. monthly, at the end of each program, etc.)
- Establish document retention requirements (e.g. attendee lists, copies of medical and promotional materials distributed, expense receipts, etc.)
- Require notification if vendor is under or comes under investigation



Questions?

Diana Borges

(215) 591-8143 diana.borges@tevausa.com

Brian Dahl, Esq.

(816) 508-5146 brian.dahl@tevausa.com

Michele Girdharry

(646) 277-2237 mgirdharry@huronconsultinggroup.com

Paul Silver

(678) 672-6160 Atlanta Office (646) 520-0200 New York Office psilver@huronconsultinggroup.com

